#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-15	MiR-137-derived	_
1-2	16-25	polygenic	_
1-3	26-30	risk	_
1-4	31-32	:	_
1-5	33-40	effects	_
1-6	41-43	on	_
1-7	44-53	cognitive	_
1-8	54-65	performance	_
1-9	66-68	in	_
1-10	69-77	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-11	78-82	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-12	83-96	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-13	97-100	and	_
1-14	101-109	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
1-15	110-118	Variants	_
1-16	119-121	at	_
1-17	122-134	microRNA-137	_
1-18	135-136	(	_
1-19	137-143	MIR137	_
1-20	144-145	)	_
1-21	146-147	,	_
1-22	148-151	one	_
1-23	152-154	of	_
1-24	155-158	the	_
1-25	159-163	most	_
1-26	164-172	strongly	_
1-27	173-183	associated	_
1-28	184-197	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-29	198-202	risk	_
1-30	203-207	loci	_
1-31	208-218	identified	_
1-32	219-221	to	_
1-33	222-226	date	_
1-34	227-228	,	_
1-35	229-233	have	_
1-36	234-238	been	_
1-37	239-249	associated	_
1-38	250-254	with	_
1-39	255-261	poorer	_
1-40	262-271	cognitive	_
1-41	272-283	performance	_
1-42	284-285	.	_

2-1	286-288	As	_
2-2	289-301	microRNA-137	_
2-3	302-304	is	_
2-4	305-310	known	_
2-5	311-313	to	_
2-6	314-322	regulate	_
2-7	323-326	the	_
2-8	327-337	expression	_
2-9	338-340	of	_
2-10	341-346	~1900	_
2-11	347-352	other	_
2-12	353-358	genes	_
2-13	359-360	,	_
2-14	361-370	including	_
2-15	371-378	several	_
2-16	379-383	that	_
2-17	384-387	are	_
2-18	388-401	independently	_
2-19	402-412	associated	_
2-20	413-417	with	_
2-21	418-431	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-22	432-433	,	_
2-23	434-436	we	_
2-24	437-443	tested	_
2-25	444-451	whether	_
2-26	452-456	this	_
2-27	457-461	gene	_
2-28	462-465	set	_
2-29	466-469	was	_
2-30	470-474	also	_
2-31	475-485	associated	_
2-32	486-490	with	_
2-33	491-500	variation	_
2-34	501-503	in	_
2-35	504-513	cognitive	_
2-36	514-525	performance	_
2-37	526-527	.	_

3-1	528-531	Our	_
3-2	532-540	analysis	_
3-3	541-544	was	_
3-4	545-550	based	_
3-5	551-553	on	_
3-6	554-556	an	_
3-7	557-568	empirically	_
3-8	569-576	derived	_
3-9	577-581	list	_
3-10	582-584	of	_
3-11	585-590	genes	_
3-12	591-596	whose	_
3-13	597-607	expression	_
3-14	608-611	was	_
3-15	612-619	altered	_
3-16	620-622	by	_
3-17	623-635	manipulation	_
3-18	636-638	of	_
3-19	639-645	MIR137	_
3-20	646-656	expression	_
3-21	657-658	.	_

4-1	659-663	This	_
4-2	664-668	list	_
4-3	669-672	was	_
4-4	673-689	cross-referenced	_
4-5	690-694	with	_
4-6	695-706	genome-wide	_
4-7	707-720	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-8	721-732	association	_
4-9	733-737	data	_
4-10	738-740	to	_
4-11	741-750	construct	_
4-12	751-761	individual	_
4-13	762-771	polygenic	_
4-14	772-778	scores	_
4-15	779-780	.	_

5-1	781-783	We	_
5-2	784-788	then	_
5-3	789-795	tested	_
5-4	796-797	,	_
5-5	798-800	in	_
5-6	801-802	a	_
5-7	803-809	sample	_
5-8	810-812	of	_
5-9	813-816	808	_
5-10	817-825	patients	_
5-11	826-829	and	_
5-12	830-833	192	_
5-13	834-842	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-14	843-844	,	_
5-15	845-852	whether	_
5-16	853-858	these	_
5-17	859-863	risk	_
5-18	864-870	scores	_
5-19	871-875	were	_
5-20	876-886	associated	_
5-21	887-891	with	_
5-22	892-899	altered	_
5-23	900-911	performance	_
5-24	912-914	on	_
5-25	915-924	cognitive	_
5-26	925-934	functions	_
5-27	935-940	known	_
5-28	941-943	to	_
5-29	944-946	be	_
5-30	947-955	affected	_
5-31	956-958	in	_
5-32	959-972	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-33	973-974	.	_

6-1	975-976	A	_
6-2	977-985	subgroup	_
6-3	986-988	of	_
6-4	989-996	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
6-5	997-1009	participants	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
6-6	1010-1014	also	_
6-7	1015-1024	underwent	_
6-8	1025-1035	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-9	1036-1043	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-10	1044-1050	during	_
6-11	1051-1057	memory	_
6-12	1058-1059	(	_
6-13	1060-1065	n=108	_
6-14	1066-1067	)	_
6-15	1068-1071	and	_
6-16	1072-1076	face	_
6-17	1077-1087	processing	_
6-18	1088-1093	tasks	_
6-19	1094-1095	(	_
6-20	1096-1100	n=83	_
6-21	1101-1102	)	_
6-22	1103-1104	.	_

7-1	1105-1114	Increased	_
7-2	1115-1124	polygenic	_
7-3	1125-1129	risk	_
7-4	1130-1136	within	_
7-5	1137-1140	the	_
7-6	1141-1152	empirically	_
7-7	1153-1160	derived	_
7-8	1161-1168	miR-137	_
7-9	1169-1178	regulated	_
7-10	1179-1183	gene	_
7-11	1184-1189	score	_
7-12	1190-1193	was	_
7-13	1194-1204	associated	_
7-14	1205-1209	with	_
7-15	1210-1223	significantly	_
7-16	1224-1229	lower	_
7-17	1230-1241	performance	_
7-18	1242-1244	on	_
7-19	1245-1257	intelligence	_
7-20	1258-1266	quotient	_
7-21	1267-1268	,	_
7-22	1269-1276	working	_
7-23	1277-1283	memory	_
7-24	1284-1287	and	_
7-25	1288-1296	episodic	_
7-26	1297-1303	memory	_
7-27	1304-1305	.	_

8-1	1306-1311	These	_
8-2	1312-1319	effects	_
8-3	1320-1324	were	_
8-4	1325-1333	observed	_
8-5	1334-1338	most	_
8-6	1339-1346	clearly	_
8-7	1347-1349	at	_
8-8	1350-1351	a	_
8-9	1352-1361	polygenic	_
8-10	1362-1371	threshold	_
8-11	1372-1374	of	_
8-12	1375-1381	P=0.05	_
8-13	1382-1383	,	_
8-14	1384-1392	although	_
8-15	1393-1404	significant	_
8-16	1405-1412	results	_
8-17	1413-1417	were	_
8-18	1418-1426	observed	_
8-19	1427-1429	at	_
8-20	1430-1433	all	_
8-21	1434-1439	three	_
8-22	1440-1450	thresholds	_
8-23	1451-1459	analyzed	_
8-24	1460-1461	.	_

9-1	1462-1466	This	_
9-2	1467-1478	association	_
9-3	1479-1482	was	_
9-4	1483-1488	found	_
9-5	1489-1502	independently	_
9-6	1503-1506	for	_
9-7	1507-1510	the	_
9-8	1511-1515	gene	_
9-9	1516-1519	set	_
9-10	1520-1522	as	_
9-11	1523-1524	a	_
9-12	1525-1530	whole	_
9-13	1531-1532	,	_
9-14	1533-1542	excluding	_
9-15	1543-1546	the	_
9-16	1547-1571	schizophrenia-associated	_
9-17	1572-1578	MIR137	_
9-18	1579-1582	SNP	_
9-19	1583-1589	itself	_
9-20	1590-1591	.	_

10-1	1592-1600	Analysis	_
10-2	1601-1603	of	_
10-3	1604-1607	the	_
10-4	1608-1615	spatial	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
10-5	1616-1623	working	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
10-6	1624-1630	memory	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
10-7	1631-1635	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
10-8	1636-1640	task	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
10-9	1641-1648	further	_
10-10	1649-1658	suggested	_
10-11	1659-1663	that	_
10-12	1664-1673	increased	_
10-13	1674-1678	risk	_
10-14	1679-1684	score	_
10-15	1685-1686	(	_
10-16	1687-1698	thresholded	_
10-17	1699-1701	at	_
10-18	1702-1708	P=10−5	_
10-19	1709-1710	)	_
10-20	1711-1714	was	_
10-21	1715-1728	significantly	_
10-22	1729-1739	associated	_
10-23	1740-1744	with	_
10-24	1745-1754	increased	_
10-25	1755-1765	activation	_
10-26	1766-1768	of	_
10-27	1769-1772	the	_
10-28	1773-1778	right	_
10-29	1779-1787	inferior	_
10-30	1788-1797	occipital	_
10-31	1798-1803	gyrus	_
10-32	1804-1805	.	_

11-1	1806-1808	In	_
11-2	1809-1819	conclusion	_
11-3	1820-1821	,	_
11-4	1822-1827	these	_
11-5	1828-1832	data	_
11-6	1833-1836	are	_
11-7	1837-1847	consistent	_
11-8	1848-1852	with	_
11-9	1853-1861	emerging	_
11-10	1862-1870	evidence	_
11-11	1871-1875	that	_
11-12	1876-1882	MIR137	_
11-13	1883-1893	associated	_
11-14	1894-1898	risk	_
11-15	1899-1902	for	_
11-16	1903-1916	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-17	1917-1920	may	_
11-18	1921-1927	relate	_
11-19	1928-1930	to	_
11-20	1931-1934	its	_
11-21	1935-1942	broader	_
11-22	1943-1953	downstream	_
11-23	1954-1961	genetic	_
11-24	1962-1969	effects	_
11-25	1970-1971	.	_

12-1	1972-1981	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-2	1982-1985	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-3	1986-1993	methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-4	1994-2006	Participants	_
12-5	2007-2009	In	_
12-6	2010-2015	total	_
12-7	2016-2017	,	_
12-8	2018-2021	808	_
12-9	2022-2027	cases	_
12-10	2028-2031	and	_
12-11	2032-2035	192	_
12-12	2036-2043	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
12-13	2044-2056	participants	_
12-14	2057-2066	completed	_
12-15	2067-2068	a	_
12-16	2069-2073	full	_
12-17	2074-2092	neuropsychological	_
12-18	2093-2103	assessment	_
12-19	2104-2111	battery	_
12-20	2112-2115	and	_
12-21	2116-2119	had	_
12-22	2120-2124	full	_
12-23	2125-2136	genome-wide	_
12-24	2137-2140	SNP	_
12-25	2141-2145	data	_
12-26	2146-2155	available	_
12-27	2156-2157	.	_

13-1	2158-2163	Cases	_
13-2	2164-2173	consisted	_
13-3	2174-2176	of	_
13-4	2177-2182	n=585	_
13-5	2183-2193	clinically	_
13-6	2194-2200	stable	_
13-7	2201-2209	patients	_
13-8	2210-2214	with	_
13-9	2215-2216	a	_
13-10	2217-2226	diagnosis	_
13-11	2227-2229	of	_
13-12	2230-2232	SZ	http://maven.renci.org/NeuroBridge/neurobridge#PhysicalMeasurement
13-13	2233-2236	and	http://maven.renci.org/NeuroBridge/neurobridge#PhysicalMeasurement
13-14	2237-2252	schizoaffective	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
13-15	2253-2261	disorder	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
13-16	2262-2263	(	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
13-17	2264-2267	SZA	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
13-18	2268-2269	)	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
13-19	2270-2271	,	_
13-20	2272-2277	which	_
13-21	2278-2280	we	_
13-22	2281-2286	refer	_
13-23	2287-2289	to	_
13-24	2290-2292	as	_
13-25	2293-2294	‘	_
13-26	2295-2307	narrow-sense	_
13-27	2308-2309	’	_
13-28	2310-2319	psychosis	_
13-29	2320-2321	,	_
13-30	2322-2325	and	_
13-31	2326-2328	an	_
13-32	2329-2339	additional	_
13-33	2340-2345	n=223	_
13-34	2346-2354	patients	_
13-35	2355-2364	diagnosed	_
13-36	2365-2369	with	_
13-37	2370-2377	bipolar	_
13-38	2378-2386	disorder	_
13-39	2387-2391	with	_
13-40	2392-2401	psychotic	_
13-41	2402-2410	features	_
13-42	2411-2412	,	_
13-43	2413-2418	major	_
13-44	2419-2429	depressive	_
13-45	2430-2438	disorder	_
13-46	2439-2443	with	_
13-47	2444-2453	psychotic	_
13-48	2454-2462	features	_
13-49	2463-2464	,	_
13-50	2465-2475	delusional	_
13-51	2476-2484	disorder	_
13-52	2485-2486	,	_
13-53	2487-2489	or	_
13-54	2490-2499	psychosis	_
13-55	2500-2503	not	_
13-56	2504-2513	otherwise	_
13-57	2514-2523	specified	_
13-58	2524-2527	who	_
13-59	2528-2536	combined	_
13-60	2537-2541	with	_
13-61	2542-2548	SZ/SZA	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
13-62	2549-2557	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
13-63	2558-2560	to	_
13-64	2561-2565	form	_
13-65	2566-2567	a	_
13-66	2568-2569	‘	_
13-67	2570-2581	broad-sense	_
13-68	2582-2583	’	_
13-69	2584-2593	psychosis	_
13-70	2594-2599	group	_
13-71	2600-2601	.	_

14-1	2602-2610	Patients	_
14-2	2611-2615	were	_
14-3	2616-2625	diagnosed	_
14-4	2626-2628	by	_
14-5	2629-2636	trained	_
14-6	2637-2650	psychiatrists	_
14-7	2651-2656	using	_
14-8	2657-2660	the	_
14-9	2661-2671	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
14-10	2672-2680	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
14-11	2681-2690	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
14-12	2691-2694	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
14-13	2695-2701	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
14-14	2702-2706	Axis	_
14-15	2707-2708	I	_
14-16	2709-2718	Diagnosis	_
14-17	2719-2720	.	_

15-1	2721-2730	Inclusion	_
15-2	2731-2739	criteria	_
15-3	2740-2748	required	_
15-4	2749-2761	participants	_
15-5	2762-2764	to	_
15-6	2765-2767	be	_
15-7	2768-2778	clinically	_
15-8	2779-2785	stable	_
15-9	2786-2788	at	_
15-10	2789-2793	time	_
15-11	2794-2796	of	_
15-12	2797-2806	cognitive	_
15-13	2807-2817	assessment	_
15-14	2818-2819	,	_
15-15	2820-2824	aged	_
15-16	2825-2832	between	_
15-17	2833-2835	18	_
15-18	2836-2839	and	_
15-19	2840-2842	65	_
15-20	2843-2848	years	_
15-21	2849-2850	,	_
15-22	2851-2853	no	_
15-23	2854-2861	history	_
15-24	2862-2864	of	_
15-25	2865-2874	co-morbid	_
15-26	2875-2886	psychiatric	_
15-27	2887-2895	disorder	_
15-28	2896-2897	,	_
15-29	2898-2900	no	_
15-30	2901-2910	substance	_
15-31	2911-2916	abuse	_
15-32	2917-2919	in	_
15-33	2920-2923	the	_
15-34	2924-2933	preceding	_
15-35	2934-2935	6	_
15-36	2936-2942	months	_
15-37	2943-2944	,	_
15-38	2945-2947	no	_
15-39	2948-2953	prior	_
15-40	2954-2958	head	_
15-41	2959-2965	injury	_
15-42	2966-2970	with	_
15-43	2971-2975	loss	_
15-44	2976-2978	of	_
15-45	2979-2992	consciousness	_
15-46	2993-2994	,	_
15-47	2995-2997	no	_
15-48	2998-3005	history	_
15-49	3006-3008	of	_
15-50	3009-3017	seizures	_
15-51	3018-3019	,	_
15-52	3020-3023	and	_
15-53	3024-3028	with	_
15-54	3029-3034	Irish	_
15-55	3035-3043	ancestry	_
15-56	3044-3045	(	_
15-57	3046-3049	all	_
15-58	3050-3054	four	_
15-59	3055-3067	grandparents	_
15-60	3068-3072	born	_
15-61	3073-3075	in	_
15-62	3076-3083	Ireland	_
15-63	3084-3085	)	_
15-64	3086-3087	.	_

16-1	3088-3095	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
16-2	3096-3108	participants	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
16-3	3109-3113	were	_
16-4	3114-3123	recruited	_
16-5	3124-3128	from	_
16-6	3129-3132	the	_
16-7	3133-3140	general	_
16-8	3141-3151	population	_
16-9	3152-3159	through	_
16-10	3160-3165	local	_
16-11	3166-3171	media	_
16-12	3172-3186	advertisements	_
16-13	3187-3188	.	_

17-1	3189-3192	All	_
17-2	3193-3197	were	_
17-3	3198-3202	aged	_
17-4	3203-3210	between	_
17-5	3211-3213	18	_
17-6	3214-3217	and	_
17-7	3218-3220	65	_
17-8	3221-3226	years	_
17-9	3227-3230	and	_
17-10	3231-3234	had	_
17-11	3235-3245	Irish-born	_
17-12	3246-3254	paternal	_
17-13	3255-3258	and	_
17-14	3259-3267	maternal	_
17-15	3268-3280	grandparents	_
17-16	3281-3282	,	_
17-17	3283-3286	and	_
17-18	3287-3296	satisfied	_
17-19	3297-3298	,	_
17-20	3299-3301	on	_
17-21	3302-3305	the	_
17-22	3306-3311	basis	_
17-23	3312-3314	of	_
17-24	3315-3323	clinical	_
17-25	3324-3333	interview	_
17-26	3334-3335	,	_
17-27	3336-3339	the	_
17-28	3340-3348	criteria	_
17-29	3349-3351	of	_
17-30	3352-3358	having	_
17-31	3359-3361	no	_
17-32	3362-3369	history	_
17-33	3370-3372	of	_
17-34	3373-3378	major	_
17-35	3379-3385	mental	_
17-36	3386-3392	health	_
17-37	3393-3401	problems	_
17-38	3402-3403	,	_
17-39	3404-3416	intellectual	_
17-40	3417-3427	disability	_
17-41	3428-3430	or	_
17-42	3431-3439	acquired	_
17-43	3440-3445	brain	_
17-44	3446-3452	injury	_
17-45	3453-3454	,	_
17-46	3455-3458	and	_
17-47	3459-3461	no	_
17-48	3462-3471	substance	_
17-49	3472-3477	abuse	_
17-50	3478-3480	in	_
17-51	3481-3484	the	_
17-52	3485-3494	preceding	_
17-53	3495-3496	6	_
17-54	3497-3503	months	_
17-55	3504-3505	.	_

18-1	3506-3515	Exclusion	_
18-2	3516-3524	criteria	_
18-3	3525-3529	also	_
18-4	3530-3538	included	_
18-5	3539-3545	having	_
18-6	3546-3547	a	_
18-7	3548-3560	first-degree	_
18-8	3561-3569	relative	_
18-9	3570-3574	with	_
18-10	3575-3576	a	_
18-11	3577-3584	history	_
18-12	3585-3587	of	_
18-13	3588-3597	psychosis	_
18-14	3598-3599	.	_

19-1	3600-3603	All	_
19-2	3604-3612	clinical	_
19-3	3613-3616	and	_
19-4	3617-3635	neuropsychological	_
19-5	3636-3647	assessments	_
19-6	3648-3652	were	_
19-7	3653-3662	conducted	_
19-8	3663-3665	in	_
19-9	3666-3676	accordance	_
19-10	3677-3681	with	_
19-11	3682-3685	the	_
19-12	3686-3694	relevant	_
19-13	3695-3701	ethics	_
19-14	3702-3712	committees	_
19-15	3713-3714	’	_
19-16	3715-3723	approval	_
19-17	3724-3727	for	_
19-18	3728-3731	the	_
19-19	3732-3735	six	_
19-20	3736-3741	sites	_
19-21	3742-3744	at	_
19-22	3745-3750	which	_
19-23	3751-3755	this	_
19-24	3756-3760	data	_
19-25	3761-3764	was	_
19-26	3765-3774	collected	_
19-27	3775-3776	,	_
19-28	3777-3780	and	_
19-29	3781-3784	all	_
19-30	3785-3797	participants	_
19-31	3798-3806	provided	_
19-32	3807-3814	written	_
19-33	3815-3823	informed	_
19-34	3824-3831	consent	_
19-35	3832-3833	.	_

20-1	3834-3843	Cognitive	_
20-2	3844-3854	assessment	_
20-3	3855-3856	A	_
20-4	3857-3861	full	_
20-5	3862-3880	neuropsychological	_
20-6	3881-3891	assessment	_
20-7	3892-3900	designed	_
20-8	3901-3903	to	_
20-9	3904-3912	evaluate	_
20-10	3913-3916	the	_
20-11	3917-3926	cognitive	_
20-12	3927-3935	deficits	_
20-13	3936-3945	typically	_
20-14	3946-3954	reported	_
20-15	3955-3957	in	_
20-16	3958-3960	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
20-17	3961-3962	(	_
20-18	3963-3970	general	_
20-19	3971-3980	cognitive	_
20-20	3981-3988	ability	_
20-21	3989-3990	,	_
20-22	3991-3997	memory	_
20-23	3998-4006	function	_
20-24	4007-4008	,	_
20-25	4009-4018	attention	_
20-26	4019-4020	,	_
20-27	4021-4024	and	_
20-28	4025-4031	social	_
20-29	4032-4041	cognition	_
20-30	4042-4043	)	_
20-31	4044-4047	was	_
20-32	4048-4060	administered	_
20-33	4061-4063	to	_
20-34	4064-4068	each	_
20-35	4069-4080	participant	_
20-36	4081-4082	.	_

21-1	4083-4091	Selected	_
21-2	4092-4100	subtests	_
21-3	4101-4102	(	_
21-4	4103-4113	Vocabulary	_
21-5	4114-4115	,	_
21-6	4116-4128	Similarities	_
21-7	4129-4130	,	_
21-8	4131-4136	Block	_
21-9	4137-4143	Design	_
21-10	4144-4145	,	_
21-11	4146-4149	and	_
21-12	4150-4156	Matrix	_
21-13	4157-4166	Reasoning	_
21-14	4167-4168	)	_
21-15	4169-4171	of	_
21-16	4172-4175	the	_
21-17	4176-4184	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
21-18	4185-4190	Adult	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
21-19	4191-4203	Intelligence	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
21-20	4204-4209	Scale	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
21-21	4210-4211	,	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
21-22	4212-4215	3rd	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
21-23	4216-4223	Edition	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
21-24	4224-4225	(	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
21-25	4226-4230	WAIS	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
21-26	4231-4234	III	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
21-27	4235-4236	)	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
21-28	4237-4241	were	_
21-29	4242-4246	used	_
21-30	4247-4249	to	_
21-31	4250-4257	measure	_
21-32	4258-4265	general	_
21-33	4266-4275	cognitive	_
21-34	4276-4284	function	_
21-35	4285-4286	.	_

22-1	4287-4290	The	_
22-2	4291-4298	Logical	http://maven.renci.org/NeuroBridge/neurobridge#EcologicalStudy
22-3	4299-4305	Memory	http://maven.renci.org/NeuroBridge/neurobridge#EcologicalStudy
22-4	4306-4307	(	http://maven.renci.org/NeuroBridge/neurobridge#EcologicalStudy
22-5	4308-4310	LM	http://maven.renci.org/NeuroBridge/neurobridge#EcologicalStudy
22-6	4311-4312	)	http://maven.renci.org/NeuroBridge/neurobridge#EcologicalStudy
22-7	4313-4314	I	_
22-8	4315-4318	and	_
22-9	4319-4321	II	_
22-10	4322-4325	and	_
22-11	4326-4331	Faces	_
22-12	4332-4333	I	http://maven.renci.org/NeuroBridge/neurobridge#Type1DiabetesMellitus
22-13	4334-4337	and	_
22-14	4338-4340	II	_
22-15	4341-4349	subtests	_
22-16	4350-4354	from	_
22-17	4355-4358	the	_
22-18	4359-4367	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#Revised
22-19	4368-4374	Memory	http://maven.renci.org/NeuroBridge/neurobridge#Revised
22-20	4375-4380	Scale	http://maven.renci.org/NeuroBridge/neurobridge#Revised
22-21	4381-4382	,	http://maven.renci.org/NeuroBridge/neurobridge#Revised
22-22	4383-4386	3rd	http://maven.renci.org/NeuroBridge/neurobridge#Revised
22-23	4387-4394	Edition	http://maven.renci.org/NeuroBridge/neurobridge#Revised
22-24	4395-4396	(	http://maven.renci.org/NeuroBridge/neurobridge#Revised
22-25	4397-4400	WMS	_
22-26	4401-4404	III	http://maven.renci.org/NeuroBridge/neurobridge#Thing
22-27	4405-4406	)	http://maven.renci.org/NeuroBridge/neurobridge#Thing
22-28	4407-4411	were	_
22-29	4412-4416	used	_
22-30	4417-4419	to	_
22-31	4420-4426	assess	_
22-32	4427-4435	episodic	_
22-33	4436-4439	and	_
22-34	4440-4446	visual	_
22-35	4447-4453	memory	_
22-36	4454-4455	.	_

23-1	4456-4463	Working	_
23-2	4464-4470	memory	_
23-3	4471-4474	was	_
23-4	4475-4483	assessed	_
23-5	4484-4489	using	_
23-6	4490-4493	the	_
23-7	4494-4501	Spatial	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
23-8	4502-4509	Working	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
23-9	4510-4516	Memory	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
23-10	4517-4518	(	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
23-11	4519-4522	SWM	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
23-12	4523-4524	)	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
23-13	4525-4532	subtest	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
23-14	4533-4537	from	_
23-15	4538-4541	the	_
23-16	4542-4551	Cambridge	_
23-17	4552-4561	Automated	_
23-18	4562-4580	Neuropsychological	_
23-19	4581-4585	Test	_
23-20	4586-4593	Battery	_
23-21	4594-4597	and	_
23-22	4598-4611	Letter-Number	_
23-23	4612-4622	Sequencing	_
23-24	4623-4627	from	_
23-25	4628-4631	the	_
23-26	4632-4635	WMS	_
23-27	4636-4639	III	_
23-28	4640-4641	.	_

24-1	4642-4653	Attentional	_
24-2	4654-4661	control	_
24-3	4662-4665	was	_
24-4	4666-4674	assessed	_
24-5	4675-4680	using	_
24-6	4681-4684	the	_
24-7	4685-4695	Continuous	_
24-8	4696-4707	Performance	http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale
24-9	4708-4712	Task	http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale
24-10	4713-4714	(	http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale
24-11	4715-4718	CPT	http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale
24-12	4719-4720	)	http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale
24-13	4721-4730	identical	_
24-14	4731-4736	pairs	_
24-15	4737-4744	version	_
24-16	4745-4748	and	_
24-17	4749-4752	the	_
24-18	4753-4762	Sustained	http://maven.renci.org/NeuroBridge/neurobridge#TreatmentResponseProgressScale
24-19	4763-4772	Attention	http://maven.renci.org/NeuroBridge/neurobridge#TreatmentResponseProgressScale
24-20	4773-4775	to	http://maven.renci.org/NeuroBridge/neurobridge#TreatmentResponseProgressScale
24-21	4776-4784	Response	http://maven.renci.org/NeuroBridge/neurobridge#TreatmentResponseProgressScale
24-22	4785-4789	Task	http://maven.renci.org/NeuroBridge/neurobridge#TreatmentResponseProgressScale
24-23	4790-4791	(	http://maven.renci.org/NeuroBridge/neurobridge#TreatmentResponseProgressScale
24-24	4792-4796	SART	http://maven.renci.org/NeuroBridge/neurobridge#TreatmentResponseProgressScale
24-25	4797-4798	)	http://maven.renci.org/NeuroBridge/neurobridge#TreatmentResponseProgressScale
24-26	4799-4800	.	_

25-1	4801-4803	In	_
25-2	4804-4812	addition	_
25-3	4813-4815	to	_
25-4	4816-4834	neuropsychological	_
25-5	4835-4845	assessment	_
25-6	4846-4847	,	_
25-7	4848-4852	this	_
25-8	4853-4858	study	_
25-9	4859-4867	included	_
25-10	4868-4876	measures	_
25-11	4877-4879	of	_
25-12	4880-4883	two	_
25-13	4884-4891	aspects	_
25-14	4892-4894	of	_
25-15	4895-4901	social	_
25-16	4902-4918	cognition—theory	_
25-17	4919-4921	of	_
25-18	4922-4926	mind	_
25-19	4927-4928	(	_
25-20	4929-4932	ToM	_
25-21	4933-4934	)	_
25-22	4935-4936	(	_
25-23	4937-4947	frequently	_
25-24	4948-4955	altered	_
25-25	4956-4961	among	_
25-26	4962-4970	patients	_
25-27	4971-4975	with	_
25-28	4976-4978	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
25-29	4979-4982	and	_
25-30	4983-4993	previously	_
25-31	4994-5004	associated	_
25-32	5005-5009	with	_
25-33	5010-5016	MIR137	_
25-34	5017-5018	(	_
25-35	5019-5022	ref	_
25-36	5023-5024	.	_
25-37	5025-5026	)	_
25-38	5027-5028	)	_

26-1	5029-5032	and	_
26-2	5033-5046	attributional	_
26-3	5047-5052	style	_
26-4	5053-5054	.	_

27-1	5055-5058	ToM	_
27-2	5059-5061	is	_
27-3	5062-5065	the	_
27-4	5066-5073	ability	_
27-5	5074-5076	to	_
27-6	5077-5086	attribute	_
27-7	5087-5093	mental	_
27-8	5094-5108	states—beliefs	_
27-9	5109-5110	,	_
27-10	5111-5118	intents	_
27-11	5119-5120	,	_
27-12	5121-5128	desires	_
27-13	5129-5130	,	_
27-14	5131-5141	pretending	_
27-15	5142-5143	,	_
27-16	5144-5153	knowledge	_
27-17	5154-5157	and	_
27-18	5158-5160	so	_
27-19	5161-5166	on—to	_
27-20	5167-5174	oneself	_
27-21	5175-5178	and	_
27-22	5179-5185	others	_
27-23	5186-5189	and	_
27-24	5190-5192	to	_
27-25	5193-5203	understand	_
27-26	5204-5208	that	_
27-27	5209-5215	others	_
27-28	5216-5220	have	_
27-29	5221-5228	beliefs	_
27-30	5229-5230	,	_
27-31	5231-5238	desires	_
27-32	5239-5240	,	_
27-33	5241-5251	intentions	_
27-34	5252-5255	and	_
27-35	5256-5268	perspectives	_
27-36	5269-5273	that	_
27-37	5274-5277	are	_
27-38	5278-5287	different	_
27-39	5288-5292	from	_
27-40	5293-5296	one	_
27-41	5297-5299	's	_
27-42	5300-5303	own	_
27-43	5304-5305	,	_
27-44	5306-5309	and	_
27-45	5310-5312	is	_
27-46	5313-5322	estimated	_
27-47	5323-5328	using	_
27-48	5329-5332	the	_
27-49	5333-5340	Reading	_
27-50	5341-5344	the	_
27-51	5345-5349	Mind	_
27-52	5350-5352	in	_
27-53	5353-5356	the	_
27-54	5357-5361	Eyes	_
27-55	5362-5366	Task	_
27-56	5367-5370	and	_
27-57	5371-5374	the	_
27-58	5375-5382	Hinting	_
27-59	5383-5387	Task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
27-60	5388-5389	.	_

28-1	5390-5403	Attributional	_
28-2	5404-5409	style	_
28-3	5410-5416	refers	_
28-4	5417-5419	to	_
28-5	5420-5423	the	_
28-6	5424-5433	pervasive	_
28-7	5434-5442	tendency	_
28-8	5443-5445	to	_
28-9	5446-5453	explain	_
28-10	5454-5464	personally	_
28-11	5465-5476	significant	_
28-12	5477-5483	events	_
28-13	5484-5486	in	_
28-14	5487-5488	a	_
28-15	5489-5499	particular	_
28-16	5500-5506	manner	_
28-17	5507-5508	.	_

29-1	5509-5520	Consistency	_
29-2	5521-5523	in	_
29-3	5524-5533	cognitive	_
29-4	5534-5544	assessment	_
29-5	5545-5548	was	_
29-6	5549-5557	assessed	_
29-7	5558-5564	across	_
29-8	5565-5570	sites	_
29-9	5571-5573	by	_
29-10	5574-5576	an	_
29-11	5577-5588	independent	_
29-12	5589-5599	researcher	_
29-13	5600-5607	marking	_
29-14	5608-5609	a	_
29-15	5610-5616	number	_
29-16	5617-5619	of	_
29-17	5620-5628	patients	_
29-18	5629-5637	assessed	_
29-19	5638-5640	at	_
29-20	5641-5645	each	_
29-21	5646-5650	site	_
29-22	5651-5652	.	_

30-1	5653-5663	Genotyping	_
30-2	5664-5674	Genotyping	_
30-3	5675-5678	was	_
30-4	5679-5688	conducted	_
30-5	5689-5691	on	_
30-6	5692-5695	DNA	_
30-7	5696-5705	extracted	_
30-8	5706-5710	from	_
30-9	5711-5716	whole	_
30-10	5717-5722	blood	_
30-11	5723-5725	or	_
30-12	5726-5732	saliva	_
30-13	5733-5734	.	_

31-1	5735-5739	Full	_
31-2	5740-5744	GWAS	_
31-3	5745-5749	data	_
31-4	5750-5754	were	_
31-5	5755-5764	available	_
31-6	5765-5768	for	_
31-7	5769-5772	all	_
31-8	5773-5780	samples	_
31-9	5781-5782	.	_

32-1	5783-5784	A	_
32-2	5785-5795	proportion	_
32-3	5796-5798	of	_
32-4	5799-5806	samples	_
32-5	5807-5811	were	_
32-6	5812-5821	genotyped	_
32-7	5822-5826	with	_
32-8	5827-5829	an	_
32-9	5830-5840	Affymetrix	_
32-10	5841-5844	6.0	_
32-11	5845-5849	chip	_
32-12	5850-5851	(	_
32-13	5852-5857	Santa	_
32-14	5858-5863	Clara	_
32-15	5864-5865	,	_
32-16	5866-5868	CA	_
32-17	5869-5870	,	_
32-18	5871-5874	USA	_
32-19	5875-5876	;	_
32-20	5877-5879	as	_
32-21	5880-5884	part	_
32-22	5885-5887	of	_
32-23	5888-5891	the	_
32-24	5892-5898	WTCCC2	_
32-25	5899-5900	,	_
32-26	5901-5909	referred	_
32-27	5910-5912	to	_
32-28	5913-5915	as	_
32-29	5916-5922	Sample	_
32-30	5923-5924	A	_
32-31	5925-5926	)	_
32-32	5927-5930	and	_
32-33	5931-5934	the	_
32-34	5935-5944	remainder	_
32-35	5945-5947	on	_
32-36	5948-5951	the	_
32-37	5952-5960	Illumina	_
32-38	5961-5975	HumanCoreExome	_
32-39	5976-5980	chip	_
32-40	5981-5982	(	_
32-41	5983-5986	San	_
32-42	5987-5992	Diego	_
32-43	5993-5994	,	_
32-44	5995-5997	CA	_
32-45	5998-5999	,	_
32-46	6000-6003	USA	_
32-47	6004-6005	;	_
32-48	6006-6014	referred	_
32-49	6015-6017	to	_
32-50	6018-6020	as	_
32-51	6021-6027	Sample	_
32-52	6028-6029	B	_
32-53	6030-6031	)	_
32-54	6032-6033	.	_

33-1	6034-6038	SNPs	_
33-2	6039-6043	were	_
33-3	6044-6052	excluded	_
33-4	6053-6055	on	_
33-5	6056-6059	the	_
33-6	6060-6065	basis	_
33-7	6066-6068	of	_
33-8	6069-6072	MAF	_
33-9	6073-6074	<	_
33-10	6075-6078	0.1	_
33-11	6079-6080	%	_
33-12	6081-6082	,	_
33-13	6083-6086	SNP	_
33-14	6087-6098	missingness	_
33-15	6099-6101	⩽2	_
33-16	6102-6103	%	_
33-17	6104-6105	,	_
33-18	6106-6109	and	_
33-19	6110-6124	Hardy–Weinberg	_
33-20	6125-6136	equilibrium	_
33-21	6137-6143	P⩽10−6	_
33-22	6144-6145	.	_

34-1	6146-6156	Imputation	_
34-2	6157-6160	was	_
34-3	6161-6168	carried	_
34-4	6169-6172	out	_
34-5	6173-6175	on	_
34-6	6176-6181	these	_
34-7	6182-6186	data	_
34-8	6187-6191	sets	_
34-9	6192-6202	separately	_
34-10	6203-6208	using	_
34-11	6209-6213	1000	_
34-12	6214-6221	Genomes	_
34-13	6222-6227	Phase	_
34-14	6228-6229	I	_
34-15	6230-6240	integrated	_
34-16	6241-6251	haplotypes	_
34-17	6252-6253	(	_
34-18	6254-6257	Dec	_
34-19	6258-6262	2013	_
34-20	6263-6270	release	_
34-21	6271-6272	)	_
34-22	6273-6276	and	_
34-23	6277-6284	IMPUTE2	_
34-24	6285-6287	to	_
34-25	6288-6292	give	_
34-26	6293-6296	~10	_
34-27	6297-6304	million	_
34-28	6305-6309	SNPs	_
34-29	6310-6321	genome-wide	_
34-30	6322-6325	per	_
34-31	6326-6332	sample	_
34-32	6333-6334	.	_

35-1	6335-6343	Polygene	_
35-2	6344-6349	score	_
35-3	6350-6352	We	_
35-4	6353-6358	began	_
35-5	6359-6361	by	_
35-6	6362-6374	constructing	_
35-7	6375-6378	the	_
35-8	6379-6386	miR-137	_
35-9	6387-6397	downstream	_
35-10	6398-6405	pathway	_
35-11	6406-6411	based	_
35-12	6412-6414	on	_
35-13	6415-6418	the	_
35-14	6419-6422	set	_
35-15	6423-6425	of	_
35-16	6426-6430	1016	_
35-17	6431-6436	genes	_
35-18	6437-6442	whose	_
35-19	6443-6453	expression	_
35-20	6454-6457	was	_
35-21	6458-6468	identified	_
35-22	6469-6471	as	_
35-23	6472-6477	being	_
35-24	6478-6485	altered	_
35-25	6486-6488	by	_
35-26	6489-6496	miR-137	_
35-27	6497-6509	manipulation	_
35-28	6510-6512	in	_
35-29	6513-6516	the	_
35-30	6517-6522	study	_
35-31	6523-6525	by	_
35-32	6526-6530	Hill	_
35-33	6531-6533	et	_
35-34	6534-6537	al.	_
35-35	6538-6539	,	_
35-36	6540-6543	831	_
35-37	6544-6546	of	_
35-38	6547-6552	these	_
35-39	6553-6558	genes	_
35-40	6559-6564	could	_
35-41	6565-6567	be	_
35-42	6568-6581	unambiguously	_
35-43	6582-6588	mapped	_
35-44	6589-6591	to	_
35-45	6592-6595	the	_
35-46	6596-6605	autosomes	_
35-47	6606-6609	and	_
35-48	6610-6614	this	_
35-49	6615-6619	gene	_
35-50	6620-6623	set	_
35-51	6624-6627	was	_
35-52	6628-6632	used	_
35-53	6633-6635	to	_
35-54	6636-6644	generate	_
35-55	6645-6653	polygene	_
35-56	6654-6660	scores	_
35-57	6661-6662	.	_

36-1	6663-6665	We	_
36-2	6666-6670	then	_
36-3	6671-6687	cross-referenced	_
36-4	6688-6692	with	_
36-5	6693-6703	unweighted	_
36-6	6704-6712	P-values	_
36-7	6713-6717	from	_
36-8	6718-6721	the	_
36-9	6722-6726	PGC2	_
36-10	6727-6731	2014	_
36-11	6732-6736	GWAS	_
36-12	6737-6740	for	_
36-13	6741-6749	variants	_
36-14	6750-6756	within	_
36-15	6757-6759	20	_
36-16	6760-6762	kb	_
36-17	6763-6765	of	_
36-18	6766-6770	each	_
36-19	6771-6775	gene	_
36-20	6776-6778	in	_
36-21	6779-6783	this	_
36-22	6784-6787	set	_
36-23	6788-6795	without	_
36-24	6796-6806	LD-pruning	_
36-25	6807-6808	(	_
36-26	6809-6815	scores	_
36-27	6816-6820	with	_
36-28	6821-6824	and	_
36-29	6825-6832	without	_
36-30	6833-6840	pruning	_
36-31	6841-6845	were	_
36-32	6846-6852	highly	_
36-33	6853-6863	correlated	_
36-34	6864-6865	)	_
36-35	6866-6867	.	_

37-1	6868-6870	We	_
37-2	6871-6875	next	_
37-3	6876-6883	defined	_
37-4	6884-6889	three	_
37-5	6890-6899	arbitrary	_
37-6	6900-6909	threshold	_
37-7	6910-6916	values	_
37-8	6917-6922	based	_
37-9	6923-6925	on	_
37-10	6926-6929	the	_
37-11	6930-6933	PGC	_
37-12	6934-6943	threshold	_
37-13	6944-6950	values	_
37-14	6951-6952	(	_
37-15	6953-6954	P	_
37-16	6955-6956	<	_
37-17	6957-6961	10−5	_
37-18	6962-6963	,	_
37-19	6964-6965	P	_
37-20	6966-6967	<	_
37-21	6968-6972	0.05	_
37-22	6973-6974	,	_
37-23	6975-6978	and	_
37-24	6979-6980	P	_
37-25	6981-6982	<	_
37-26	6983-6986	0.5	_
37-27	6987-6988	)	_
37-28	6989-6991	to	_
37-29	6992-7000	generate	_
37-30	7001-7006	three	_
37-31	7007-7015	polygene	_
37-32	7016-7020	risk	_
37-33	7021-7026	score	_
37-34	7027-7033	values	_
37-35	7034-7037	for	_
37-36	7038-7046	analysis	_
37-37	7047-7048	.	_

38-1	7049-7054	Using	_
38-2	7055-7060	these	_
38-3	7061-7071	thresholds	_
38-4	7072-7073	,	_
38-5	7074-7078	1020	_
38-6	7079-7080	,	_
38-7	7081-7083	20	_
38-8	7084-7087	920	_
38-9	7088-7091	and	_
38-10	7092-7094	89	_
38-11	7095-7098	102	_
38-12	7099-7103	SNPs	_
38-13	7104-7108	were	_
38-14	7109-7117	included	_
38-15	7118-7120	in	_
38-16	7121-7124	the	_
38-17	7125-7133	analysis	_
38-18	7134-7135	,	_
38-19	7136-7148	respectively	_
38-20	7149-7150	.	_

39-1	7151-7158	Finally	_
39-2	7159-7160	,	_
39-3	7161-7165	each	_
39-4	7166-7177	participant	_
39-5	7178-7181	was	_
39-6	7182-7186	then	_
39-7	7187-7192	given	_
39-8	7193-7194	a	_
39-9	7195-7203	weighted	_
39-10	7204-7212	polygene	_
39-11	7213-7218	score	_
39-12	7219-7224	based	_
39-13	7225-7227	on	_
39-14	7228-7231	the	_
39-15	7232-7238	number	_
39-16	7239-7241	of	_
39-17	7242-7246	risk	_
39-18	7247-7254	alleles	_
39-19	7255-7259	they	_
39-20	7260-7267	carried	_
39-21	7268-7274	within	_
39-22	7275-7279	this	_
39-23	7280-7284	gene	_
39-24	7285-7289	list	_
39-25	7290-7292	at	_
39-26	7293-7296	the	_
39-27	7297-7302	given	_
39-28	7303-7307	gene	_
39-29	7308-7317	threshold	_
39-30	7318-7319	,	_
39-31	7320-7328	weighted	_
39-32	7329-7331	by	_
39-33	7332-7335	the	_
39-34	7336-7339	log	_
39-35	7340-7342	of	_
39-36	7343-7346	the	_
39-37	7347-7361	SZ-association	_
39-38	7362-7366	odds	_
39-39	7367-7372	ratio	_
39-40	7373-7377	from	_
39-41	7378-7381	the	_
39-42	7382-7386	PGC2	_
39-43	7387-7388	.	_

40-1	7389-7394	Genes	_
40-2	7395-7399	used	_
40-3	7400-7402	in	_
40-4	7403-7407	this	_
40-5	7408-7415	process	_
40-6	7416-7419	are	_
40-7	7420-7425	found	_
40-8	7426-7428	in	_
40-9	7429-7432	the	_
40-10	7433-7446	Supplementary	_
40-11	7447-7458	Information	_
40-12	7459-7460	.	_

41-1	7461-7472	Statistical	_
41-2	7473-7481	analysis	_
41-3	7482-7483	:	_
41-4	7484-7502	neuropsychological	_
41-5	7503-7508	tests	_
41-6	7509-7512	and	_
41-7	7513-7521	polygene	_
41-8	7522-7528	scores	_
41-9	7529-7533	Data	_
41-10	7534-7538	were	_
41-11	7539-7548	inspected	_
41-12	7549-7552	for	_
41-13	7553-7571	heteroscedasticity	_
41-14	7572-7573	,	_
41-15	7574-7577	and	_
41-16	7578-7586	outliers	_
41-17	7587-7588	,	_
41-18	7589-7594	which	_
41-19	7595-7599	were	_
41-20	7600-7608	excluded	_
41-21	7609-7613	from	_
41-22	7614-7622	analysis	_
41-23	7623-7624	.	_

42-1	7625-7627	To	_
42-2	7628-7636	estimate	_
42-3	7637-7645	polygene	_
42-4	7646-7653	effects	_
42-5	7654-7656	on	_
42-6	7657-7666	cognitive	_
42-7	7667-7675	deficits	_
42-8	7676-7686	associated	_
42-9	7687-7691	with	_
42-10	7692-7694	SZ	_
42-11	7695-7696	(	_
42-12	7697-7709	intelligence	_
42-13	7710-7718	quotient	_
42-14	7719-7720	(	_
42-15	7721-7723	IQ	_
42-16	7724-7725	)	_
42-17	7726-7727	,	_
42-18	7728-7734	memory	_
42-19	7735-7736	,	_
42-20	7737-7748	attentional	_
42-21	7749-7756	control	_
42-22	7757-7760	and	_
42-23	7761-7767	social	_
42-24	7768-7777	cognition	_
42-25	7778-7779	)	_
42-26	7780-7786	linear	_
42-27	7787-7797	regression	_
42-28	7798-7806	analyses	_
42-29	7807-7811	were	_
42-30	7812-7821	performed	_
42-31	7822-7827	using	_
42-32	7828-7831	IBM	_
42-33	7832-7836	SPSS	_
42-34	7837-7847	Statistics	_
42-35	7848-7849	,	_
42-36	7850-7854	with	_
42-37	7855-7858	age	_
42-38	7859-7862	and	_
42-39	7863-7869	gender	_
42-40	7870-7877	entered	_
42-41	7878-7880	as	_
42-42	7881-7890	variables	_
42-43	7891-7893	of	_
42-44	7894-7896	no	_
42-45	7897-7905	interest	_
42-46	7906-7907	,	_
42-47	7908-7911	and	_
42-48	7912-7916	test	_
42-49	7917-7922	score	_
42-50	7923-7925	as	_
42-51	7926-7929	the	_
42-52	7930-7939	dependent	_
42-53	7940-7948	variable	_
42-54	7949-7950	.	_

43-1	7951-7953	To	_
43-2	7954-7958	take	_
43-3	7959-7963	into	_
43-4	7964-7971	account	_
43-5	7972-7981	potential	_
43-6	7982-7993	differences	_
43-7	7994-7996	in	_
43-8	7997-8004	results	_
43-9	8005-8012	between	_
43-10	8013-8019	Sample	_
43-11	8020-8021	A	_
43-12	8022-8025	and	_
43-13	8026-8027	B	_
43-14	8028-8031	due	_
43-15	8032-8034	to	_
43-16	8035-8038	the	_
43-17	8039-8042	two	_
43-18	8043-8052	differing	_
43-19	8053-8063	genotyping	_
43-20	8064-8073	platforms	_
43-21	8074-8078	used	_
43-22	8079-8080	,	_
43-23	8081-8082	a	_
43-24	8083-8089	linear	_
43-25	8090-8100	regression	_
43-26	8101-8104	was	_
43-27	8105-8114	performed	_
43-28	8115-8125	separately	_
43-29	8126-8128	in	_
43-30	8129-8133	each	_
43-31	8134-8140	sample	_
43-32	8141-8142	(	_
43-33	8143-8148	those	_
43-34	8149-8158	genotyped	_
43-35	8159-8164	using	_
43-36	8165-8175	Affymetrix	_
43-37	8176-8179	and	_
43-38	8180-8185	those	_
43-39	8186-8190	with	_
43-40	8191-8199	Illumina	_
43-41	8200-8201	)	_
43-42	8202-8203	.	_

44-1	8204-8211	Results	_
44-2	8212-8216	from	_
44-3	8217-8222	these	_
44-4	8223-8227	were	_
44-5	8228-8232	then	_
44-6	8233-8246	meta-analyzed	_
44-7	8247-8252	using	_
44-8	8253-8256	the	_
44-9	8257-8264	inverse	_
44-10	8265-8273	variance	_
44-11	8274-8280	method	_
44-12	8281-8282	.	_

45-1	8283-8285	In	_
45-2	8286-8289	the	_
45-3	8290-8297	inverse	_
45-4	8298-8306	variance	_
45-5	8307-8313	method	_
45-6	8314-8315	,	_
45-7	8316-8319	the	_
45-8	8320-8326	weight	_
45-9	8327-8332	given	_
45-10	8333-8335	to	_
45-11	8336-8340	each	_
45-12	8341-8347	sample	_
45-13	8348-8350	is	_
45-14	8351-8357	chosen	_
45-15	8358-8360	to	_
45-16	8361-8363	be	_
45-17	8364-8367	the	_
45-18	8368-8375	inverse	_
45-19	8376-8378	of	_
45-20	8379-8382	the	_
45-21	8383-8391	variance	_
45-22	8392-8394	of	_
45-23	8395-8398	the	_
45-24	8399-8405	effect	_
45-25	8406-8414	estimate	_
45-26	8415-8416	(	_
45-27	8417-8421	that	_
45-28	8422-8424	is	_
45-29	8425-8426	,	_
45-30	8427-8430	one	_
45-31	8431-8435	over	_
45-32	8436-8439	the	_
45-33	8440-8446	square	_
45-34	8447-8449	of	_
45-35	8450-8453	its	_
45-36	8454-8462	standard	_
45-37	8463-8468	error	_
45-38	8469-8470	)	_
45-39	8471-8472	.	_

46-1	8473-8477	This	_
46-2	8478-8487	minimizes	_
46-3	8488-8491	the	_
46-4	8492-8503	imprecision	_
46-5	8504-8506	of	_
46-6	8507-8510	the	_
46-7	8511-8517	pooled	_
46-8	8518-8524	effect	_
46-9	8525-8533	estimate	_
46-10	8534-8535	.	_

47-1	8536-8538	An	_
47-2	8539-8547	estimate	_
47-3	8548-8550	of	_
47-4	8551-8557	sample	_
47-5	8558-8571	heterogeneity	_
47-6	8572-8575	and	_
47-7	8576-8588	significance	_
47-8	8589-8591	of	_
47-9	8592-8596	such	_
47-10	8597-8599	is	_
47-11	8600-8605	shown	_
47-12	8606-8608	in	_
47-13	8609-8622	Supplementary	_
47-14	8623-8628	Table	_
47-15	8629-8630	1	_
47-16	8631-8632	(	_
47-17	8633-8635	I2	_
47-18	8636-8637	)	_
47-19	8638-8639	.	_

48-1	8640-8642	To	_
48-2	8643-8651	maximize	_
48-3	8652-8657	power	_
48-4	8658-8660	to	_
48-5	8661-8667	detect	_
48-6	8668-8679	differences	_
48-7	8680-8681	,	_
48-8	8682-8684	we	_
48-9	8685-8692	carried	_
48-10	8693-8696	out	_
48-11	8697-8700	our	_
48-12	8701-8709	analysis	_
48-13	8710-8712	on	_
48-14	8713-8716	the	_
48-15	8717-8721	full	_
48-16	8722-8729	dataset	_
48-17	8730-8732	of	_
48-18	8733-8736	all	_
48-19	8737-8742	cases	_
48-20	8743-8746	and	_
48-21	8747-8755	controls	_
48-22	8756-8757	(	_
48-23	8758-8764	n=1000	_
48-24	8765-8766	)	_
48-25	8767-8768	.	_

49-1	8769-8771	We	_
49-2	8772-8776	then	_
49-3	8777-8785	followed	_
49-4	8786-8789	any	_
49-5	8790-8801	significant	_
49-6	8802-8809	results	_
49-7	8810-8812	in	_
49-8	8813-8816	the	_
49-9	8817-8824	patient	_
49-10	8825-8829	only	_
49-11	8830-8836	groups	_
49-12	8837-8838	(	_
49-13	8839-8843	both	_
49-14	8844-8847	the	_
49-15	8848-8853	broad	_
49-16	8854-8863	psychosis	_
49-17	8864-8869	group	_
49-18	8870-8871	(	_
49-19	8872-8877	n=808	_
49-20	8878-8879	)	_
49-21	8880-8883	and	_
49-22	8884-8890	narrow	_
49-23	8891-8900	psychosis	_
49-24	8901-8906	group	_
49-25	8907-8908	(	_
49-26	8909-8917	patients	_
49-27	8918-8922	with	_
49-28	8923-8925	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
49-29	8926-8929	and	_
49-30	8930-8945	schizoaffective	_
49-31	8946-8954	disorder	_
49-32	8955-8959	only	_
49-33	8960-8961	(	_
49-34	8962-8967	n=585	_
49-35	8968-8969	)	_
49-36	8970-8971	)	_
49-37	8972-8974	to	_
49-38	8975-8982	confirm	_
49-39	8983-8986	the	_
49-40	8987-8996	direction	_
49-41	8997-8999	of	_
49-42	9000-9007	effects	_
49-43	9008-9010	in	_
49-44	9011-9016	these	_
49-45	9017-9023	groups	_
49-46	9024-9025	(	_
49-47	9026-9039	Supplementary	_
49-48	9040-9046	Tables	_
49-49	9047-9048	2	_
49-50	9049-9052	and	_
49-51	9053-9054	3	_
49-52	9055-9056	)	_
49-53	9057-9058	.	_

50-1	9059-9061	As	_
50-2	9062-9065	the	_
50-3	9066-9079	meta-analyses	_
50-4	9080-9086	showed	_
50-5	9087-9093	little	_
50-6	9094-9102	evidence	_
50-7	9103-9105	of	_
50-8	9106-9119	heterogeneity	_
50-9	9120-9122	of	_
50-10	9123-9130	results	_
50-11	9131-9133	in	_
50-12	9134-9140	Sample	_
50-13	9141-9142	A	_
50-14	9143-9146	and	_
50-15	9147-9148	B	_
50-16	9149-9156	despite	_
50-17	9157-9160	the	_
50-18	9161-9170	differing	_
50-19	9171-9179	genotype	_
50-20	9180-9189	platforms	_
50-21	9190-9191	,	_
50-22	9192-9195	the	_
50-23	9196-9202	sample	_
50-24	9203-9206	was	_
50-25	9207-9215	analyzed	_
50-26	9216-9218	as	_
50-27	9219-9220	a	_
50-28	9221-9226	whole	_
50-29	9227-9229	to	_
50-30	9230-9237	provide	_
50-31	9238-9240	an	_
50-32	9241-9249	estimate	_
50-33	9250-9252	of	_
50-34	9253-9259	effect	_
50-35	9260-9264	size	_
50-36	9265-9272	provide	_
50-37	9273-9275	r2	_
50-38	9276-9279	and	_
50-39	9280-9292	standardized	_
50-40	9293-9294	β	_
50-41	9295-9301	values	_
50-42	9302-9303	(	_
50-43	9304-9317	Supplementary	_
50-44	9318-9323	Table	_
50-45	9324-9325	4	_
50-46	9326-9327	)	_
50-47	9328-9329	.	_

51-1	9330-9331	A	_
51-2	9332-9336	post	_
51-3	9337-9340	hoc	_
51-4	9341-9346	power	_
51-5	9347-9358	calculation	_
51-6	9359-9368	estimated	_
51-7	9369-9373	that	_
51-8	9374-9379	n=988	_
51-9	9380-9383	has	_
51-10	9384-9388	0.88	_
51-11	9389-9394	power	_
51-12	9395-9397	to	_
51-13	9398-9404	detect	_
51-14	9405-9406	a	_
51-15	9407-9411	very	_
51-16	9412-9424	conservative	_
51-17	9425-9433	polygene	_
51-18	9434-9439	score	_
51-19	9440-9446	effect	_
51-20	9447-9449	of	_
51-21	9450-9457	r2=0.01	_
51-22	9458-9459	,	_
51-23	9460-9464	with	_
51-24	9465-9471	α=0.05	_
51-25	9472-9473	,	_
51-26	9474-9482	although	_
51-27	9483-9488	there	_
51-28	9489-9492	are	_
51-29	9493-9500	certain	_
51-30	9501-9508	caveats	_
51-31	9509-9511	to	_
51-32	9512-9516	this	_
51-33	9517-9521	type	_
51-34	9522-9524	of	_
51-35	9525-9536	calculation	_
51-36	9537-9538	.	_

52-1	9539-9549	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
52-2	9550-9553	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
52-3	9554-9555	A	_
52-4	9556-9564	subgroup	_
52-5	9565-9567	of	_
52-6	9568-9571	the	_
52-7	9572-9579	healthy	_
52-8	9580-9592	participants	_
52-9	9593-9595	in	_
52-10	9596-9600	this	_
52-11	9601-9606	study	_
52-12	9607-9608	(	_
52-13	9609-9612	all	_
52-14	9613-9618	right	_
52-15	9619-9625	handed	_
52-16	9626-9627	)	_
52-17	9628-9631	had	_
52-18	9632-9636	also	_
52-19	9637-9646	undergone	_
52-20	9647-9657	functional	_
52-21	9658-9665	imaging	_
52-22	9666-9672	during	_
52-23	9673-9676	two	_
52-24	9677-9686	cognitive	_
52-25	9687-9692	tasks	_
52-26	9693-9694	.	_

53-1	9695-9698	One	_
53-2	9699-9706	hundred	_
53-3	9707-9712	eight	_
53-4	9713-9725	participants	_
53-5	9726-9735	completed	_
53-6	9736-9737	a	_
53-7	9738-9745	spatial	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
53-8	9746-9753	working	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
53-9	9754-9760	memory	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
53-10	9761-9765	task	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
53-11	9766-9769	and	_
53-12	9770-9772	83	_
53-13	9773-9776	had	_
53-14	9777-9786	completed	_
53-15	9787-9788	a	_
53-16	9789-9795	facial	http://maven.renci.org/NeuroBridge/neurobridge#AffectiveProcessingScale
53-17	9796-9806	processing	http://maven.renci.org/NeuroBridge/neurobridge#AffectiveProcessingScale
53-18	9807-9811	task	http://maven.renci.org/NeuroBridge/neurobridge#AffectiveProcessingScale
53-19	9812-9813	,	_
53-20	9814-9818	with	_
53-21	9819-9824	tasks	_
53-22	9825-9828	and	_
53-23	9829-9840	acquisition	_
53-24	9841-9851	parameters	_
53-25	9852-9854	as	_
53-26	9855-9864	described	_
53-27	9865-9867	by	_
53-28	9868-9870	us	_
53-29	9871-9881	previously	_
53-30	9882-9883	.	_

54-1	9884-9887	The	_
54-2	9888-9892	task	_
54-3	9893-9896	can	_
54-4	9897-9899	be	_
54-5	9900-9910	summarized	_
54-6	9911-9913	as	_
54-7	9914-9921	follows	_
54-8	9922-9923	.	_

55-1	9924-9931	Spatial	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
55-2	9932-9939	working	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
55-3	9940-9946	memory	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
55-4	9947-9951	task	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
55-5	9952-9956	This	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
55-6	9957-9962	block	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
55-7	9963-9969	design	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
55-8	9970-9974	task	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
55-9	9975-9978	was	_
55-10	9979-9988	presented	_
55-11	9989-9994	using	_
55-12	9995-10007	Presentation	_
55-13	10008-10016	software	_
55-14	10017-10018	(	_
55-15	10019-10034	Neurobehavioral	_
55-16	10035-10042	Systems	_
55-17	10043-10044	,	_
55-18	10045-10051	Albany	_
55-19	10052-10053	,	_
55-20	10054-10056	CA	_
55-21	10057-10058	,	_
55-22	10059-10062	USA	_
55-23	10063-10064	)	_
55-24	10065-10066	.	_

56-1	10067-10079	Participants	_
56-2	10080-10084	were	_
56-3	10085-10090	asked	_
56-4	10091-10093	if	_
56-5	10094-10095	a	_
56-6	10096-10101	white	_
56-7	10102-10105	dot	_
56-8	10106-10109	was	_
56-9	10110-10112	in	_
56-10	10113-10116	the	_
56-11	10117-10121	same	_
56-12	10122-10129	spatial	_
56-13	10130-10138	location	_
56-14	10139-10141	as	_
56-15	10142-10143	a	_
56-16	10144-10147	red	_
56-17	10148-10154	circle	_
56-18	10155-10156	(	_
56-19	10157-10170	Supplementary	_
56-20	10171-10177	Figure	_
56-21	10178-10179	1	_
56-22	10180-10181	)	_
56-23	10182-10188	during	_
56-24	10189-10194	three	_
56-25	10195-10205	conditions	_
56-26	10206-10207	.	_

57-1	10208-10210	In	_
57-2	10211-10214	the	_
57-3	10215-10223	baseline	_
57-4	10224-10233	condition	_
57-5	10234-10237	the	_
57-6	10238-10243	white	_
57-7	10244-10247	dot	_
57-8	10248-10251	and	_
57-9	10252-10255	red	_
57-10	10256-10262	circle	_
57-11	10263-10267	both	_
57-12	10268-10274	appear	_
57-13	10275-10277	at	_
57-14	10278-10281	the	_
57-15	10282-10286	same	_
57-16	10287-10291	time	_
57-17	10292-10293	.	_

58-1	10294-10296	In	_
58-2	10297-10300	the	_
58-3	10301-10306	1-dot	_
58-4	10307-10316	condition	_
58-5	10317-10318	,	_
58-6	10319-10322	the	_
58-7	10323-10328	white	_
58-8	10329-10332	dot	_
58-9	10333-10336	and	_
58-10	10337-10340	red	_
58-11	10341-10347	circle	_
58-12	10348-10351	are	_
58-13	10352-10361	separated	_
58-14	10362-10364	by	_
58-15	10365-10366	a	_
58-16	10367-10369	3-	_
58-17	10370-10371	s	_
58-18	10372-10377	delay	_
58-19	10378-10379	.	_

59-1	10380-10387	Finally	_
59-2	10388-10389	,	_
59-3	10390-10392	in	_
59-4	10393-10396	the	_
59-5	10397-10402	3-dot	_
59-6	10403-10412	condition	_
59-7	10413-10414	,	_
59-8	10415-10416	3	_
59-9	10417-10422	white	_
59-10	10423-10427	dots	_
59-11	10428-10431	and	_
59-12	10432-10433	a	_
59-13	10434-10437	red	_
59-14	10438-10444	circle	_
59-15	10445-10448	are	_
59-16	10449-10458	presented	_
59-17	10459-10460	,	_
59-18	10461-10470	separated	_
59-19	10471-10473	by	_
59-20	10474-10475	a	_
59-21	10476-10478	3-	_
59-22	10479-10480	s	_
59-23	10481-10486	delay	_
59-24	10487-10488	.	_

60-1	10489-10493	Task	_
60-2	10494-10502	accuracy	_
60-3	10503-10506	and	_
60-4	10507-10515	reaction	_
60-5	10516-10520	time	_
60-6	10521-10525	were	_
60-7	10526-10530	also	_
60-8	10531-10539	measured	_
60-9	10540-10541	.	_

61-1	10542-10545	Out	_
61-2	10546-10548	of	_
61-3	10549-10552	108	_
61-4	10553-10565	participants	_
61-5	10566-10567	,	_
61-6	10568-10573	there	_
61-7	10574-10578	were	_
61-8	10579-10580	3	_
61-9	10581-10588	missing	_
61-10	10589-10593	this	_
61-11	10594-10604	behavioral	_
61-12	10605-10609	data	_
61-13	10610-10614	that	_
61-14	10615-10619	were	_
61-15	10620-10628	excluded	_
61-16	10629-10633	from	_
61-17	10634-10638	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
61-18	10639-10647	analysis	_
61-19	10648-10649	,	_
61-20	10650-10653	and	_
61-21	10654-10657	one	_
61-22	10658-10669	participant	_
61-23	10670-10673	was	_
61-24	10674-10682	excluded	_
61-25	10683-10686	due	_
61-26	10687-10689	to	_
61-27	10690-10692	an	_
61-28	10693-10698	error	_
61-29	10699-10703	with	_
61-30	10704-10707	the	_
61-31	10708-10712	task	_
61-32	10713-10717	that	_
61-33	10718-10724	caused	_
61-34	10725-10727	it	_
61-35	10728-10730	to	_
61-36	10731-10734	run	_
61-37	10735-10738	for	_
61-38	10739-10746	several	_
61-39	10747-10754	seconds	_
61-40	10755-10760	after	_
61-41	10761-10764	the	_
61-42	10765-10769	scan	_
61-43	10770-10778	finished	_
61-44	10779-10780	.	_

62-1	10781-10784	Two	_
62-2	10785-10795	additional	_
62-3	10796-10808	participants	_
62-4	10809-10813	were	_
62-5	10814-10822	excluded	_
62-6	10823-10827	from	_
62-7	10828-10836	analysis	_
62-8	10837-10840	due	_
62-9	10841-10843	to	_
62-10	10844-10852	movement	_
62-11	10853-10856	and	_
62-12	10857-10859	16	_
62-13	10860-10864	were	_
62-14	10865-10873	excluded	_
62-15	10874-10878	from	_
62-16	10879-10882	all	_
62-17	10883-10891	analysis	_
62-18	10892-10895	due	_
62-19	10896-10898	to	_
62-20	10899-10910	low-quality	_
62-21	10911-10914	MRI	_
62-22	10915-10919	data	_
62-23	10920-10921	.	_

63-1	10922-10926	This	_
63-2	10927-10931	left	_
63-3	10932-10933	a	_
63-4	10934-10939	final	_
63-5	10940-10946	sample	_
63-6	10947-10949	of	_
63-7	10950-10952	86	_
63-8	10953-10960	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
63-9	10961-10973	participants	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
63-10	10974-10975	.	_

64-1	10976-10979	The	_
64-2	10980-10989	beginning	_
64-3	10990-10992	of	_
64-4	10993-10996	the	_
64-5	10997-11004	spatial	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
64-6	11005-11012	working	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
64-7	11013-11019	memory	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
64-8	11020-11024	task	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
64-9	11025-11028	was	_
64-10	11029-11041	synchronized	_
64-11	11042-11044	to	_
64-12	11045-11048	the	_
64-13	11049-11054	first	_
64-14	11055-11076	transistor-transistor	_
64-15	11077-11082	logic	_
64-16	11083-11084	(	_
64-17	11085-11088	TTL	_
64-18	11089-11090	)	http://maven.renci.org/NeuroBridge/neurobridge#Thing
64-19	11091-11096	pulse	_
64-20	11097-11101	sent	_
64-21	11102-11106	from	_
64-22	11107-11110	the	_
64-23	11111-11114	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
64-24	11115-11122	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
64-25	11123-11125	at	_
64-26	11126-11129	the	_
64-27	11130-11135	start	_
64-28	11136-11138	of	_
64-29	11139-11142	the	_
64-30	11143-11151	sequence	_
64-31	11152-11153	.	_

65-1	11154-11161	However	_
65-2	11162-11163	,	_
65-3	11164-11167	for	_
65-4	11168-11169	a	_
65-5	11170-11178	minority	_
65-6	11179-11181	of	_
65-7	11182-11194	participants	_
65-8	11195-11198	the	_
65-9	11199-11204	start	_
65-10	11205-11207	of	_
65-11	11208-11211	the	_
65-12	11212-11216	task	_
65-13	11217-11220	was	_
65-14	11221-11224	not	_
65-15	11225-11237	synchronized	_
65-16	11238-11240	to	_
65-17	11241-11244	the	_
65-18	11245-11248	TTL	_
65-19	11249-11254	pulse	_
65-20	11255-11258	due	_
65-21	11259-11261	to	_
65-22	11262-11264	an	_
65-23	11265-11277	experimental	_
65-24	11278-11283	error	_
65-25	11284-11285	;	_
65-26	11286-11289	for	_
65-27	11290-11295	these	_
65-28	11296-11307	individuals	_
65-29	11308-11311	the	_
65-30	11312-11316	task	_
65-31	11317-11320	was	_
65-32	11321-11324	run	_
65-33	11325-11333	manually	_
65-34	11334-11336	at	_
65-35	11337-11340	the	_
65-36	11341-11346	start	_
65-37	11347-11349	of	_
65-38	11350-11353	the	_
65-39	11354-11362	sequence	_
65-40	11363-11364	.	_

66-1	11365-11368	Due	_
66-2	11369-11371	to	_
66-3	11372-11375	the	_
66-4	11376-11381	block	_
66-5	11382-11388	design	_
66-6	11389-11395	nature	_
66-7	11396-11398	of	_
66-8	11399-11403	this	_
66-9	11404-11408	task	_
66-10	11409-11410	,	_
66-11	11411-11414	any	_
66-12	11415-11420	small	_
66-13	11421-11434	discrepancies	_
66-14	11435-11437	in	_
66-15	11438-11444	timing	_
66-16	11445-11454	resulting	_
66-17	11455-11459	from	_
66-18	11460-11464	this	_
66-19	11465-11470	error	_
66-20	11471-11474	are	_
66-21	11475-11483	unlikely	_
66-22	11484-11486	to	_
66-23	11487-11493	affect	_
66-24	11494-11501	results	_
66-25	11502-11503	.	_

67-1	11504-11508	Face	_
67-2	11509-11519	processing	_
67-3	11520-11524	task	_
67-4	11525-11534	Developed	_
67-5	11535-11537	by	_
67-6	11538-11546	Grosbras	_
67-7	11547-11549	et	_
67-8	11550-11553	al.	_
67-9	11554-11555	,	_
67-10	11556-11568	participants	_
67-11	11569-11570	(	_
67-12	11571-11575	n=83	_
67-13	11576-11577	)	_
67-14	11578-11585	watched	_
67-15	11586-11587	a	_
67-16	11588-11594	series	_
67-17	11595-11597	of	_
67-18	11598-11601	2-s	_
67-19	11602-11604	to	_
67-20	11605-11608	5-s	_
67-21	11609-11614	black	_
67-22	11615-11618	and	_
67-23	11619-11624	white	_
67-24	11625-11631	videos	_
67-25	11632-11634	of	_
67-26	11635-11640	faces	_
67-27	11641-11642	,	_
67-28	11643-11648	which	_
67-29	11649-11656	started	_
67-30	11657-11661	from	_
67-31	11662-11663	a	_
67-32	11664-11671	neutral	_
67-33	11672-11682	expression	_
67-34	11683-11684	,	_
67-35	11685-11688	and	_
67-36	11689-11693	then	_
67-37	11694-11700	turned	_
67-38	11701-11705	into	_
67-39	11706-11708	an	_
67-40	11709-11714	angry	_
67-41	11715-11725	expression	_
67-42	11726-11728	or	_
67-43	11729-11736	neutral	_
67-44	11737-11747	expression	_
67-45	11748-11749	,	_
67-46	11750-11762	interspersed	_
67-47	11763-11767	with	_
67-48	11768-11769	a	_
67-49	11770-11777	control	_
67-50	11778-11787	condition	_
67-51	11788-11798	consisting	_
67-52	11799-11801	of	_
67-53	11802-11807	video	_
67-54	11808-11813	clips	_
67-55	11814-11816	of	_
67-56	11817-11822	black	_
67-57	11823-11826	and	_
67-58	11827-11832	white	_
67-59	11833-11843	concentric	_
67-60	11844-11851	circles	_
67-61	11852-11861	expanding	_
67-62	11862-11865	and	_
67-63	11866-11877	contracting	_
67-64	11878-11879	.	_

68-1	11880-11886	Blocks	_
68-2	11887-11889	of	_
68-3	11890-11895	video	_
68-4	11896-11901	clips	_
68-5	11902-11908	lasted	_
68-6	11909-11912	18-	_
68-7	11913-11914	s	_
68-8	11915-11916	,	_
68-9	11917-11921	with	_
68-10	11922-11925	4–7	_
68-11	11926-11931	video	_
68-12	11932-11937	clips	_
68-13	11938-11947	presented	_
68-14	11948-11951	per	_
68-15	11952-11957	block	_
68-16	11958-11959	.	_

69-1	11960-11967	Overall	_
69-2	11968-11969	,	_
69-3	11970-11975	there	_
69-4	11976-11980	were	_
69-5	11981-11983	19	_
69-6	11984-11990	blocks	_
69-7	11991-11992	:	_
69-8	11993-11994	5	_
69-9	11995-12001	blocks	_
69-10	12002-12004	of	_
69-11	12005-12012	neutral	_
69-12	12013-12017	face	_
69-13	12018-12024	videos	_
69-14	12025-12026	,	_
69-15	12027-12028	5	_
69-16	12029-12035	blocks	_
69-17	12036-12038	of	_
69-18	12039-12044	angry	_
69-19	12045-12049	face	_
69-20	12050-12056	videos	_
69-21	12057-12060	and	_
69-22	12061-12062	9	_
69-23	12063-12070	control	_
69-24	12071-12080	condition	_
69-25	12081-12087	blocks	_
69-26	12088-12089	(	_
69-27	12090-12095	every	_
69-28	12096-12102	second	_
69-29	12103-12108	block	_
69-30	12109-12112	was	_
69-31	12113-12114	a	_
69-32	12115-12122	control	_
69-33	12123-12128	block	_
69-34	12129-12130	)	_
69-35	12131-12132	.	_

70-1	12133-12135	To	_
70-2	12136-12140	make	_
70-3	12141-12145	sure	_
70-4	12146-12150	that	_
70-5	12151-12162	individuals	_
70-6	12163-12166	had	_
70-7	12167-12171	paid	_
70-8	12172-12181	attention	_
70-9	12182-12184	to	_
70-10	12185-12188	the	_
70-11	12189-12195	videos	_
70-12	12196-12197	,	_
70-13	12198-12202	they	_
70-14	12203-12212	performed	_
70-15	12213-12214	a	_
70-16	12215-12219	face	_
70-17	12220-12231	recognition	_
70-18	12232-12236	test	_
70-19	12237-12242	after	_
70-20	12243-12251	scanning	_
70-21	12252-12253	.	_

71-1	12254-12256	In	_
71-2	12257-12261	this	_
71-3	12262-12266	test	_
71-4	12267-12268	,	_
71-5	12269-12270	5	_
71-6	12271-12281	stil-color	_
71-7	12282-12290	pictures	_
71-8	12291-12293	of	_
71-9	12294-12299	faces	_
71-10	12300-12304	were	_
71-11	12305-12314	presented	_
71-12	12315-12318	and	_
71-13	12319-12331	participants	_
71-14	12332-12336	were	_
71-15	12337-12342	asked	_
71-16	12343-12345	to	_
71-17	12346-12355	determine	_
71-18	12356-12363	whether	_
71-19	12364-12369	these	_
71-20	12370-12377	matched	_
71-21	12378-12383	faces	_
71-22	12384-12388	seen	_
71-23	12389-12395	during	_
71-24	12396-12399	the	_
71-25	12400-12404	task	_
71-26	12405-12406	.	_

72-1	12407-12410	Six	_
72-2	12411-12423	participants	_
72-3	12424-12428	were	_
72-4	12429-12437	excluded	_
72-5	12438-12440	as	_
72-6	12441-12445	they	_
72-7	12446-12452	scored	_
72-8	12453-12457	less	_
72-9	12458-12462	than	_
72-10	12463-12466	4/5	_
72-11	12467-12474	correct	_
72-12	12475-12482	answers	_
72-13	12483-12485	or	_
72-14	12486-12490	were	_
72-15	12491-12498	missing	_
72-16	12499-12503	data	_
72-17	12504-12507	for	_
72-18	12508-12511	the	_
72-19	12512-12516	face	_
72-20	12517-12528	recognition	_
72-21	12529-12533	task	_
72-22	12534-12535	.	_

73-1	12536-12539	One	_
73-2	12540-12544	face	_
73-3	12545-12555	processing	_
73-4	12556-12567	participant	_
73-5	12568-12571	was	_
73-6	12572-12580	excluded	_
73-7	12581-12585	from	_
73-8	12586-12594	analysis	_
73-9	12595-12598	due	_
73-10	12599-12601	to	_
73-11	12602-12611	excessive	_
73-12	12612-12620	movement	_
73-13	12621-12624	and	_
73-14	12625-12626	5	_
73-15	12627-12639	participants	_
73-16	12640-12644	were	_
73-17	12645-12653	excluded	_
73-18	12654-12657	due	_
73-19	12658-12660	to	_
73-20	12661-12672	low-quality	_
73-21	12673-12676	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
73-22	12677-12681	data	_
73-23	12682-12688	and/or	_
73-24	12689-12700	significant	_
73-25	12701-12710	artefacts	_
73-26	12711-12712	,	_
73-27	12713-12722	resulting	_
73-28	12723-12725	in	_
73-29	12726-12727	a	_
73-30	12728-12733	final	_
73-31	12734-12740	sample	_
73-32	12741-12743	of	_
73-33	12744-12746	70	_
73-34	12747-12759	participants	_
73-35	12760-12761	.	_

74-1	12762-12769	Imaging	_
74-2	12770-12784	pre-processing	_
74-3	12785-12788	and	_
74-4	12789-12800	statistical	_
74-5	12801-12809	analysis	_
74-6	12810-12817	Spatial	_
74-7	12818-12832	pre-processing	_
74-8	12833-12836	and	_
74-9	12837-12848	statistical	_
74-10	12849-12857	analysis	_
74-11	12858-12860	of	_
74-12	12861-12864	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
74-13	12865-12869	data	_
74-14	12870-12873	was	_
74-15	12874-12883	performed	_
74-16	12884-12889	using	_
74-17	12890-12901	Statistical	_
74-18	12902-12912	Parametric	_
74-19	12913-12920	Mapping	_
74-20	12921-12922	(	_
74-21	12923-12927	SPM8	_
74-22	12928-12929	,	_
74-23	12930-12938	revision	_
74-24	12939-12943	4290	_
74-25	12944-12945	,	_
74-26	12946-12950	http	_
74-27	12951-12952	:	_
74-28	12953-12995	//www.fil.ion.ucl.ac.uk/spm/software/spm8/	_
74-29	12996-12997	)	_
74-30	12998-13001	and	_
74-31	13002-13008	MATLAB	_
74-32	13009-13015	R2011b	_
74-33	13016-13017	(	_
74-34	13018-13023	v7.13	_
74-35	13024-13025	;	_
74-36	13026-13030	http	_
74-37	13031-13032	:	_
74-38	13033-13055	//www.mathworks.co.uk/	_
74-39	13056-13057	)	_
74-40	13058-13059	.	_

75-1	13060-13070	Functional	_
75-2	13071-13077	images	_
75-3	13078-13082	were	_
75-4	13083-13092	realigned	_
75-5	13093-13095	to	_
75-6	13096-13099	the	_
75-7	13100-13104	mean	_
75-8	13105-13115	functional	_
75-9	13116-13121	image	_
75-10	13122-13123	,	_
75-11	13124-13134	normalized	_
75-12	13135-13137	to	_
75-13	13138-13141	MNI	_
75-14	13142-13143	(	_
75-15	13144-13152	Montreal	_
75-16	13153-13165	Neurological	_
75-17	13166-13175	Institute	_
75-18	13176-13177	)	_
75-19	13178-13183	space	_
75-20	13184-13188	with	_
75-21	13189-13190	a	_
75-22	13191-13196	voxel	_
75-23	13197-13201	size	_
75-24	13202-13204	of	_
75-25	13205-13206	3	_
75-26	13207-13208	×	_
75-27	13209-13210	3	_
75-28	13211-13212	×	_
75-29	13213-13214	3	_
75-30	13215-13218	mm3	_
75-31	13219-13222	and	_
75-32	13223-13231	smoothed	_
75-33	13232-13237	using	_
75-34	13238-13239	a	_
75-35	13240-13242	10	_
75-36	13243-13245	mm	_
75-37	13246-13250	FWHM	_
75-38	13251-13252	(	_
75-39	13253-13263	full-width	_
75-40	13264-13266	at	_
75-41	13267-13271	half	_
75-42	13272-13279	maximum	_
75-43	13280-13281	)	_
75-44	13282-13291	isotropic	_
75-45	13292-13300	Gaussian	_
75-46	13301-13307	filter	_
75-47	13308-13309	.	_

76-1	13310-13315	After	_
76-2	13316-13323	spatial	_
76-3	13324-13338	pre-processing	_
76-4	13339-13340	,	_
76-5	13341-13350	graphical	_
76-6	13351-13356	plots	_
76-7	13357-13359	of	_
76-8	13360-13363	the	_
76-9	13364-13373	estimated	_
76-10	13374-13378	time	_
76-11	13379-13385	series	_
76-12	13386-13388	of	_
76-13	13389-13401	translations	_
76-14	13402-13405	and	_
76-15	13406-13415	rotations	_
76-16	13416-13420	were	_
76-17	13421-13430	inspected	_
76-18	13431-13434	for	_
76-19	13435-13444	excessive	_
76-20	13445-13451	motion	_
76-21	13452-13453	,	_
76-22	13454-13459	which	_
76-23	13460-13462	we	_
76-24	13463-13470	defined	_
76-25	13471-13473	as	_
76-26	13474-13478	more	_
76-27	13479-13483	than	_
76-28	13484-13485	3	_
76-29	13486-13488	mm	_
76-30	13489-13500	translation	_
76-31	13501-13507	and/or	_
76-32	13508-13510	3°	_
76-33	13511-13519	rotation	_
76-34	13520-13521	.	_

77-1	13522-13525	For	_
77-2	13526-13529	the	_
77-3	13530-13537	spatial	_
77-4	13538-13545	working	_
77-5	13546-13552	memory	_
77-6	13553-13557	task	_
77-7	13558-13559	,	_
77-8	13560-13571	statistical	_
77-9	13572-13580	analysis	_
77-10	13581-13584	was	_
77-11	13585-13594	performed	_
77-12	13595-13600	using	_
77-13	13601-13602	a	_
77-14	13603-13610	general	_
77-15	13611-13617	linear	_
77-16	13618-13623	model	_
77-17	13624-13625	(	_
77-18	13626-13629	GLM	_
77-19	13630-13631	)	_
77-20	13632-13636	with	_
77-21	13637-13640	two	_
77-22	13641-13650	contrasts	_
77-23	13651-13652	:	_
77-24	13653-13660	spatial	_
77-25	13661-13668	working	_
77-26	13669-13675	memory	_
77-27	13676-13677	(	_
77-28	13678-13679	1	_
77-29	13680-13683	dot	_
77-30	13684-13687	and	_
77-31	13688-13689	3	_
77-32	13690-13694	dots	_
77-33	13695-13701	versus	_
77-34	13702-13710	baseline	_
77-35	13711-13712	)	_
77-36	13713-13714	,	_
77-37	13715-13718	and	_
77-38	13719-13728	increased	_
77-39	13729-13736	spatial	_
77-40	13737-13744	working	_
77-41	13745-13751	memory	_
77-42	13752-13756	load	_
77-43	13757-13758	(	_
77-44	13759-13760	3	_
77-45	13761-13765	dots	_
77-46	13766-13767	>	_
77-47	13768-13769	1	_
77-48	13770-13773	dot	_
77-49	13774-13775	)	_
77-50	13776-13777	.	_

78-1	13778-13781	For	_
78-2	13782-13785	the	_
78-3	13786-13790	face	_
78-4	13791-13801	processing	_
78-5	13802-13806	task	_
78-6	13807-13808	,	_
78-7	13809-13814	three	_
78-8	13815-13819	task	_
78-9	13820-13830	conditions	_
78-10	13831-13832	(	_
78-11	13833-13838	angry	_
78-12	13839-13844	faces	_
78-13	13845-13846	,	_
78-14	13847-13854	neutral	_
78-15	13855-13860	faces	_
78-16	13861-13864	and	_
78-17	13865-13873	baseline	_
78-18	13874-13875	)	_
78-19	13876-13879	and	_
78-20	13880-13884	four	_
78-21	13885-13894	contrasts	_
78-22	13895-13905	consistent	_
78-23	13906-13910	with	_
78-24	13911-13914	our	_
78-25	13915-13926	examination	_
78-26	13927-13929	of	_
78-27	13930-13936	neural	_
78-28	13937-13945	activity	_
78-29	13946-13956	associated	_
78-30	13957-13961	with	_
78-31	13962-13966	this	_
78-32	13967-13971	task	_
78-33	13972-13974	in	_
78-34	13975-13977	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
78-35	13978-13986	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
78-36	13987-13988	:	_
78-37	13989-13996	Neutral	_
78-38	13997-14002	faces	_
78-39	14003-14009	versus	_
78-40	14010-14018	baseline	_
78-41	14019-14020	,	_
78-42	14021-14026	angry	_
78-43	14027-14032	faces	_
78-44	14033-14039	versus	_
78-45	14040-14048	baseline	_
78-46	14049-14050	,	_
78-47	14051-14054	all	_
78-48	14055-14060	faces	_
78-49	14061-14062	(	_
78-50	14063-14068	angry	_
78-51	14069-14072	and	_
78-52	14073-14080	neutral	_
78-53	14081-14082	)	_
78-54	14083-14089	versus	_
78-55	14090-14098	baseline	_
78-56	14099-14100	,	_
78-57	14101-14104	and	_
78-58	14105-14110	angry	_
78-59	14111-14116	faces	_
78-60	14117-14123	versus	_
78-61	14124-14131	neutral	_
78-62	14132-14137	faces	_
78-63	14138-14139	.	_

79-1	14140-14152	Participants	_
79-2	14153-14154	’	_
79-3	14155-14163	contrast	_
79-4	14164-14168	maps	_
79-5	14169-14173	were	_
79-6	14174-14181	entered	_
79-7	14182-14186	into	_
79-8	14187-14188	a	_
79-9	14189-14201	second-level	_
79-10	14202-14210	analysis	_
79-11	14211-14213	to	_
79-12	14214-14225	investigate	_
79-13	14226-14233	effects	_
79-14	14234-14236	of	_
79-15	14237-14243	MIR137	_
79-16	14244-14251	network	_
79-17	14252-14254	on	_
79-18	14255-14261	neural	_
79-19	14262-14270	activity	_
79-20	14271-14272	(	_
79-21	14273-14281	multiple	_
79-22	14282-14292	regression	_
79-23	14293-14301	analysis	_
79-24	14302-14306	with	_
79-25	14307-14310	the	_
79-26	14311-14322	empirically	_
79-27	14323-14330	derived	_
79-28	14331-14338	miR-137	_
79-29	14339-14348	regulated	_
79-30	14349-14353	gene	_
79-31	14354-14359	score	_
79-32	14360-14362	as	_
79-33	14363-14372	covariate	_
79-34	14373-14375	of	_
79-35	14376-14384	interest	_
79-36	14385-14386	)	_
79-37	14387-14388	.	_

80-1	14389-14393	This	_
80-2	14394-14402	multiple	_
80-3	14403-14413	regression	_
80-4	14414-14422	analysis	_
80-5	14423-14426	was	_
80-6	14427-14436	performed	_
80-7	14437-14440	for	_
80-8	14441-14444	the	_
80-9	14445-14456	empirically	_
80-10	14457-14464	derived	_
80-11	14465-14471	MIR137	_
80-12	14472-14476	gene	_
80-13	14477-14482	score	_
80-14	14483-14485	at	_
80-15	14486-14489	the	_
80-16	14490-14496	P=10−5	_
80-17	14497-14498	,	_
80-18	14499-14505	P=0.05	_
80-19	14506-14509	and	_
80-20	14510-14515	P=0.5	_
80-21	14516-14522	levels	_
80-22	14523-14524	.	_

81-1	14525-14532	Results	_
81-2	14533-14537	were	_
81-3	14538-14546	examined	_
81-4	14547-14549	at	_
81-5	14550-14551	a	_
81-6	14552-14553	P	_
81-7	14554-14555	<	_
81-8	14556-14561	0.001	_
81-9	14562-14563	(	_
81-10	14564-14575	uncorrected	_
81-11	14576-14577	)	_
81-12	14578-14583	level	_
81-13	14584-14587	and	_
81-14	14588-14596	clusters	_
81-15	14597-14601	were	_
81-16	14602-14612	considered	_
81-17	14613-14626	statistically	_
81-18	14627-14638	significant	_
81-19	14639-14641	at	_
81-20	14642-14643	a	_
81-21	14644-14645	P	_
81-22	14646-14647	<	_
81-23	14648-14652	0.05	_
81-24	14653-14658	level	_
81-25	14659-14660	,	_
81-26	14661-14672	family-wise	_
81-27	14673-14678	error	_
81-28	14679-14680	(	_
81-29	14681-14684	FWE	_
81-30	14685-14686	)	_
81-31	14687-14696	corrected	_
81-32	14697-14700	for	_
81-33	14701-14709	multiple	_
81-34	14710-14721	comparisons	_
81-35	14722-14728	across	_
81-36	14729-14732	the	_
81-37	14733-14738	whole	_
81-38	14739-14744	brain	_
81-39	14745-14747	at	_
81-40	14748-14751	the	_
81-41	14752-14759	cluster	_
81-42	14760-14765	level	_
81-43	14766-14767	.	_

82-1	14768-14771	For	_
82-2	14772-14776	each	_
82-3	14777-14779	of	_
82-4	14780-14785	these	_
82-5	14786-14794	clusters	_
82-6	14795-14796	,	_
82-7	14797-14800	MNI	_
82-8	14801-14812	coordinates	_
82-9	14813-14815	of	_
82-10	14816-14827	significant	_
82-11	14828-14834	maxima	_
82-12	14835-14839	were	_
82-13	14840-14847	entered	_
82-14	14848-14852	into	_
82-15	14853-14856	the	_
82-16	14857-14864	Anatomy	_
82-17	14865-14872	toolbox	_
82-18	14873-14875	in	_
82-19	14876-14880	SPM8	_
82-20	14881-14882	(	_
82-21	14883-14887	refs	_
82-22	14888-14889	)	_
82-23	14890-14893	and	_
82-24	14894-14902	probable	_
82-25	14903-14913	anatomical	_
82-26	14914-14921	regions	_
82-27	14922-14926	were	_
82-28	14927-14937	identified	_
82-29	14938-14943	using	_
82-30	14944-14947	the	_
82-31	14948-14964	AllAreas_v18_MPM	_
82-32	14965-14970	atlas	_
82-33	14971-14972	.	_

